Included in the formulation
АТХ:H.03.A.A Thyroid hormones
H.03.A.A.03 Levothyroxine in combination with lyotyronine
Pharmacodynamics:As a part of the preparation synthetic thyroid hormones levothyroxine and lyotropin. The drug compensates for the deficiency of thyroid hormones. Strengthening the need for oxygen in tissues, stimulates their growth and differentiation, increases the level of basal metabolism: proteins, carbohydrates, fats. Small doses of the drug are anabolic, and large - catabolic effect. Strengthening of energy processes has a positive effect on the functions of the cardiovascular and nervous system, kidneys and liver.
Pharmacokinetics:Levothyroxine
After oral administration, an empty stomach absorbs up to 80% in the upper part of the small intestine. The maximum concentration in blood plasma is reached after 6 hours. The connection with plasma proteins is 99%.
Therapeutic effect develops 3-5 days after the beginning of the admission. Metabolism in the liver, muscles, kidneys, brain tissue.
The half-life is 6-7 days. Elimination by the kidneys.
Lyotyronin
It is absorbed in the small intestine by 95%. The maximum concentration in the blood plasma is achieved after 2-3 days.The therapeutic effect continues for 7-9 days after the end of the drug. Communication with blood proteins by 90.7%.
The half-life is 24 hours. Metabolism in the liver, muscles, kidneys, brain tissue.
Indications:It is used to treat hypothyroidism, treatment of eutheroid goiter, in order to prevent relapse after resection of the thyroid gland. It is used for thyroid cancer as an overwhelming therapy before surgery, and for substitution therapy after thyroectomy.
IV.E00-E07.E03.9 Hypothyroidism, unspecified
IV.E00-E07.E03 Other forms of hypothyroidism
II.C73-C75.C73 Malignant neoplasm of thyroid gland
Contraindications:Acute myocardial infarction, myocarditis, thyrotoxicosis, Dühring's disease (herpeticomorphic dermatitis).
Individual intolerance.
Carefully:Ischemic heart disease, heart failure, sugar and diabetes insipidus, malabsorption syndrome.
Pregnancy and lactation:Recommendations for FDA - Category B. In pregnancy, the prescribed treatment should continue, with a dose adjustment. Potassium iodide enters the breast milk, it is recommended during treatment to stop breastfeeding.
Dosing and Administration:Use in children
Children of preschool age: the initial dose of 0.25-0.5 tablets daily, then 100-150 μg / m2 surface of the body.
Pupils: 0,5-2 tablets daily.
Adults
Once inside for 30 minutes before breakfast, without chewing. The initial dose of 0.5 tablets. Gradual increase in dose every 1-2 weeks to maintain 1-2 tablets per day. Reception regular, cancellation or correction of a dose is carried out on the basis of laboratory data.
The highest daily dose: 2 tablets.
The highest single dose: 2 tablets.
Side effects:Allergic reactions.
Overdose:Symptomatic of thyrotoxicosis: tachycardia, finger tremors, exophthalmos, weight loss, hyperhidrosis.
Treatment: reduction of the dose of the drug. In cases of acute poisoning, plasmaphoresis is indicated.
Interaction:Simultaneous use with salicylates, dicumarol, clofibrate, phenytoin, furosemide enhances the effect of the drug.
The drug potentiates the effect of indirect anticoagulants.
Increases the need for hypoglycemic drugs, including insulin.
Reduces the negative dromotropic and inotropic effect of cardiac glycosides.
Simultaneous use with estrogens increases the amount of thyroxine-binding globulin.
Special instructions:Before prescribing the drug, a check should be made for the hypofunction of the adrenal cortex.